US-FDA inspection at Bengaluru facility ends with one observation
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
US-FDA conducted a routine cGMP inspection at OneSource Specialty Pharma's Sterile Product Division facility in Bengaluru from June 22 to June 30, 2026. The inspection ended with one observation, which the company will respond to within the stipulated timeframe. No details on the nature of the observation were shared.
A single observation is usually treated as minor, but markets often react cautiously until the company's response is accepted by FDA.